Newsroom
Press Releases
mQOL and Berenson Cancer Center Partner on Groundbreaking Observational Study to Enhance Oncology Care
March 27, 2025
mQOL, a pioneering digital health company, is pursuing the launch of its specialized platform designed to capture high-fidelity Patient-Reported Outcomes (PROs) including symptom status and Quality of Life (QoL) data in real-time. mQOL has validated and transformed the communication mechanisms of how patient reported outcomes are best captured and are excited to launch the platform in Oncology. With an initial focus and deep commitment to serve the multiple myeloma community, we are thrilled to announce the launch of mQOL’s prospective observational study in partnership with the highly renown Berenson Cancer Center in West Hollywood, CA. This pioneering initiative is set to evaluate the accessibility, completion rate, time burden, and clinical utility of capturing real-time symptom and Quality of Life (QoL) data for patients with multiple myeloma.
mQOL is dedicated to enhancing cancer care by empowering patients to direct PROACTIVE, timely, accurate, and actionable patient insights to healthcare providers, enabling the potential for early intervention and improved outcomes. Through our HIPAA-compliant SMS-based digital remote monitoring platform, mQOL aims to bridge critical gaps in oncology care by enabling real-time, patient-reported outcomes (PROs) that empower both patients and healthcare providers. By leveraging a seamless, app-free approach, this study will assess how consistent, high-fidelity symptom tracking can enhance patient engagement and optimize clinical decision-making. The mQOL platform is designed to handle the complexities, empowering physicians with more data, while giving patients a voice in their treatment journey.
Key Highlights of the Study:
✅ Single-center feasibility study focused on multiple myeloma patients✅ Principal Investigator, Dr. James Berenson, Principal Investigator at Berenson Cancer Center
✅ Target enrollment of 50 myeloma patients spanning newly diagnosed, relapsed/refractory, and maintenance therapy cohorts
✅ 90-day evaluation period assessing patient engagement and clinical impact in a concentrated manner
✅ Real-time monitoring and reporting to inform timely interventions determined by the study site
This study marks an important step in transforming oncology care, ensuring that Quality of Life is at the core of cancer treatment.
We look forward to sharing insights as the study progresses!
📍 Learn more about mQOL at www.mqol.com
#mQOL #OncologyCare #PatientCentered #DigitalHealth #MultipleMyeloma #RealWorldData #ClinicalResearch #PROs #QoL
Events & Presentations
Press Release 1
Change the text and add your own content, including any information that is relevant to share. Then customize the font, size and scale to make it your own.
Press Release 1
Change the text and add your own content, including any information that is relevant to share. Then customize the font, size and scale to make it your own.
Press Release 1
Change the text and add your own content, including any information that is relevant to share. Then customize the font, size and scale to make it your own.
Frequently Asked Questions:
1. Company / PlatformBackground
mQOL is a digital health company focused on capturing real-time, high-fidelity Quality of Life (QoL) and Patient-Reported Outcomes (PROs), particularly in oncology, with an initial focus on multiple myeloma patients. It addresses limitations in traditional QoL data collection by using a HIPAA-compliant, real-time, SMS-based platform that seamlessly integrates into existing clinical workflows. This provides actionable, patient-centered insights to healthcare providers, enabling them to make more informed, data-driven decisions.
The mQOL platform works through a simple, text-based system. Patients are enrolled and provide informed consent. They then receive 3-5 tailored SMS messages daily, asking them to report symptoms and emotional states on a 1-5 scale using simple Likert scale and short answer responses. The platform uses an adaptive learning system to tailor the questions over time based on the patient's responses, behavior, and engagement patterns. The platform then generates regular, synthesized reports for healthcare providers, presenting a collated view of the patient's well-being with alerts for significant changes. This system ensures that the platform remains clinically relevant and minimizes the burden on the patient while capturing critical data
-
Real-time, actionable data: Provides timely and accurate QoL data to healthcare providers, enabling them to make data-driven decisions.
-
Patient empowerment: Actively involves patients in their care journey, improving overall satisfaction and outcomes.
-
Enhanced engagement: Uses simple SMS-based interactions to achieve high levels of patient compliance and participation.
-
Improved efficiency: Seamlessly integrates into existing clinical workflows, minimizing disruption to care teams.
-
Personalized Care: The platform enables personalized, data-driven decisions that impact outcomes.
-
Potential for Reimbursement: CMS aims to improve quality and reduce costs utilizing RTM, including reimbursement incentives and billing opportunities for remote care.
-
-
Focus on Oncology and Multiple Myeloma: Specializes in capturing QoL and symptom data for cancer patients, allowing for deeper and more relevant insights.
-
SMS-Based Data Collection: Ensures high engagement rates, particularly among older or less tech-savvy patients.
-
Integration with Clinical Workflows: Designed to integrate with existing electronic health record (EHR) systems.
-
Adaptive Learning: Continuously refines the data collection process to capture the most clinically meaningful data.
-
Regulatory Focus: Built to meet stringent regulatory requirements (HIPAA, FDA), suitable for use in clinical trials and healthcare settings.
-
mQOL's data collection processes are designed to be HIPAA-compliant and meet FDA regulations for patient-reported outcomes. The platform aggregates patient data into mQOL's central platform, which can be accessed by healthcare providers through secure, HIPAA-compliant channels.
The granular, real-time data collected by mQOL can be aggregated and anonymized for use in pharmaceutical drug trials and oncology research. This data offers insights into patient experiences, treatment efficacy, and the broader impact of therapies on quality of life. mQOL is also pursuing regulatory recognition (e.g., Breakthrough Device Designation) to fast-track its approval and integration into clinical settings, further solidifying its role in oncology care.
Frequently Asked Questions:
2. General Platform Information
mQOL is a digital health platform designed to collect and analyze Patient-Reported Outcomes (PROs) and Quality of Life (QoL) data in real time. It enables patient-driven symptom tracking through a HIPAA-compliant SMS-based system, making symptom monitoring and QoL reporting routine for oncology patients, particularly those with multiple myeloma. The platform seamlessly integrates into clinical workflows, ensuring that healthcare providers receive actionable, high-fidelity patient data to improve care and outcomes.
mQOL collects PRO data using an SMS-based system that sends 3-5 daily tailored questions to patients regarding symptoms and emotional states. Responses are captured through a simple Likert scale (1-5) and short answer inputs. The platform learns from patient responses over time, adjusting the questions to optimize engagement. Healthcare providers receive real-time reports and alerts, enabling proactive interventions and data-driven decision-making.
mQOL collects longitudinal symptom and QoL data, including:
-
Physical symptoms (e.g., pain, nausea, dizziness)
-
Emotional well-being (e.g., anxiety, depression)
-
Daily activity levels
-
Treatment side effects
The platform aggregates and synthesizes this data into individual patient reports, practice-wide summaries, and trend analyses, which are delivered to healthcare providers in an easy-to-read format with visual charts and alerts for critical changes.
-
mQOL enables continuous, real-time symptom monitoring, shifting PRO data from static and infrequent surveys to a dynamic, patient-driven approach. By allowing patients to proactively report symptoms via SMS, mQOL:
-
Reduces the burden of lengthy clinic-based surveys
-
Improves communication between patients and providers
-
Empowers patients to participate in their care
-
Enhances early detection of treatment-related issues
Leads to better clinical decisions and outcomes
-
The platform identifies critical changes in patient-reported symptoms and automatically flags concerning trends for the healthcare team. These alerts help healthcare providers prioritize high-risk patients and intervene before issues escalate, reducing complications and hospitalizations.
mQOL improves PRO data quality by:
-
Ensuring consistency: Regular, structured data collection minimizes missing or incomplete data.
-
Providing real-time insights: Clinicians receive timely alerts instead of waiting for scheduled appointments.
-
Using adaptive learning: The system tailors questions over time to focus on the most clinically relevantinformation.
Minimizing patient burden: Short, SMS-based interactions reduce survey fatigue, maintaining high engagement.
-
mQOL supports CMS's Enhanced Oncology Model (EOM) by:
-
Facilitating remote therapeutic monitoring (RTM) to capture high-fidelity symptom data
-
Providing structured PRO reporting, improving quality measures and reimbursement eligibility
-
Reducing clinical workload, allowing oncologists to focus on higher-value patient care
Enhancing value-based care initiatives, aligning with CMS's goal to improve outcomes while reducing costs
-
-
Uses simple, familiar SMS messaging instead of requiring patients to download an app.
-
Sends only a few questions per day, taking less than 2 minutes to complete.
-
Adapts to patient needs, ensuring the experience is personalized and relevant.
Provides reminders if a patient forgets to respond, reducing data gaps.
-
Your provider will use mQOL data to:
-
Monitor symptom trends over time
-
Detect and address potential adverse events earlier
-
Personalize treatment plans based on real-time patient input
Improve overall quality of care and patient outcomes
-
Patients mayreceive up to 8 messages per day, but this may vary based on their treatment plan and condition.
Yes. The adaptive learning system refines questions based on:
-
The patient's diagnosis and treatment regimen
-
Past responses and engagement trends
Provider-defined monitoring needs
-
Yes, mQOL sends automated follow-up reminders if a patient does not respond within a set time.
Yes, while multiple myeloma is the initial focus, the platform is designed to support other oncology and chronic disease patients.
Yes. Studies show that engaging patients in symptom reporting leads to:
-
Higher patient satisfaction
-
Better adherence to treatment
-
Earlier detection of complications
Improved quality of life and survival rates
-
Frequently Asked Questions:
3. Accounts and Access
Patients are enrolled by their healthcare provider. They receive a welcome SMS with instructions to begin using the platform.
Since mQOL is SMS-based, there is no password required. If you are having trouble accessing reports, contact support@mqol.com.
No. Each account is tied to an individual patient and cannot be shared.
Patients should contact their healthcare provider or mQOL support to update their details.
Frequently Asked Questions:
4. Technical and System Requirements
mQOL works on any mobile phone that supports SMS texting. No specific browser or app is required.
No, mQOL operates entirely through SMS to ensure maximum accessibility.
No, as long as they have a mobile phone capable of sending and receiving text messages, they can participate.
mQOL operates entirely through SMS to ensure maximum accessibility.
No, mQOL operates entirely through SMS to ensure maximum accessibility.
No, mQOL operates entirely through SMS to ensure maximum accessibility.
Frequently Asked Questions:
5. 5 Operational and Support Services
No. We provide the data and symptoms that your care team want tracked and share that information with them so they can make treatment decisions.
No. We work with the care team treating you and listen to what they would like to be alerted too based on a change.
No. We provide the data and symptoms that your care team want tracked and share that information with them so they can make the best possible treatment decision.
Frequently Asked Questions:
6. Data Security and Compliance
-
HIPAA-compliant encryption to secure data.
-
De-identification to protect patient privacy.
-
Access controls ensuring only authorized providers can view patient data.
-
Yes, mQOL meets HIPAA and GDPR security and privacy standards.
Patients can request data deletion through their healthcare provider or support@mqol.com.
No, not yet. MQOL does intend to pursue this regulatory path in the future.
Corporate Governance
Press Release 1
Change the text and add your own content, including any information that is relevant to share. Then customize the font, size and scale to make it your own.